Cargando…
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions
Small-cell lung cancer (SCLC) is an aggressive and rapidly growing disease with poor prognosis. Despite intense efforts to improve clinical outcomes, platinum/etoposide chemotherapy has remained the most effective regimen for first-line extensive disease SCLC for decades. The addition of immune chec...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811117/ https://www.ncbi.nlm.nih.gov/pubmed/33450659 http://dx.doi.org/10.1016/j.esmoop.2020.100003 |